Natixis Advisors L.P. grew its position in shares of Anika Therapeutics Inc (NASDAQ:ANIK) by 179.7% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 157,559 shares of the biotechnology company’s stock after acquiring an additional 101,237 shares during the period. Natixis Advisors L.P.’s holdings in Anika Therapeutics were worth $6,400,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of the company. Renaissance Technologies LLC grew its stake in shares of Anika Therapeutics by 21.6% in the second quarter. Renaissance Technologies LLC now owns 444,222 shares of the biotechnology company’s stock worth $18,044,000 after purchasing an additional 78,812 shares during the last quarter. Charles Schwab Investment Management Inc. raised its position in Anika Therapeutics by 15.9% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 93,844 shares of the biotechnology company’s stock valued at $3,812,000 after purchasing an additional 12,895 shares during the last quarter. Prudential Financial Inc. raised its position in Anika Therapeutics by 67.4% during the 2nd quarter. Prudential Financial Inc. now owns 108,933 shares of the biotechnology company’s stock valued at $4,425,000 after purchasing an additional 43,860 shares during the last quarter. Alps Advisors Inc. purchased a new stake in Anika Therapeutics in the 2nd quarter worth approximately $1,208,000. Finally, C M Bidwell & Associates Ltd. purchased a new stake in Anika Therapeutics in the 2nd quarter worth approximately $44,000. 93.74% of the stock is owned by hedge funds and other institutional investors.

ANIK stock traded down $0.33 during trading on Wednesday, reaching $55.28. The company had a trading volume of 36,848 shares, compared to its average volume of 147,561. The company has a market cap of $759.44 million, a P/E ratio of 30.04, a PEG ratio of 3.15 and a beta of 1.08. The company has a debt-to-equity ratio of 0.09, a current ratio of 18.28 and a quick ratio of 16.07. The business has a 50 day moving average of $55.19 and a 200 day moving average of $40.62. Anika Therapeutics Inc has a 52 week low of $29.01 and a 52 week high of $58.93.

Anika Therapeutics (NASDAQ:ANIK) last announced its earnings results on Wednesday, July 24th. The biotechnology company reported $0.67 EPS for the quarter, beating the Zacks’ consensus estimate of $0.42 by $0.25. Anika Therapeutics had a net margin of 26.87% and a return on equity of 11.27%. The firm had revenue of $30.42 million for the quarter, compared to analysts’ expectations of $27.41 million. The company’s quarterly revenue was down .4% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.68 EPS. Research analysts expect that Anika Therapeutics Inc will post 1.75 earnings per share for the current year.

Several research firms have recently issued reports on ANIK. BidaskClub cut Anika Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, September 4th. Zacks Investment Research lowered Anika Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, July 26th. ValuEngine upgraded shares of Anika Therapeutics from a “hold” rating to a “buy” rating in a report on Wednesday, July 3rd. First Analysis raised shares of Anika Therapeutics from a “neutral” rating to a “strong-buy” rating and boosted their price objective for the company from $37.00 to $54.00 in a research report on Thursday, July 25th. Finally, Barrington Research reissued a “buy” rating and set a $49.00 price objective (up from $45.00) on shares of Anika Therapeutics in a research report on Thursday, July 25th. Three equities research analysts have rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $46.00.

In other news, Director Jeffery S. Thompson sold 4,843 shares of Anika Therapeutics stock in a transaction that occurred on Thursday, August 8th. The shares were sold at an average price of $56.66, for a total transaction of $274,404.38. Following the completion of the transaction, the director now directly owns 6,842 shares in the company, valued at $387,667.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Joseph L. Bower sold 1,994 shares of the business’s stock in a transaction that occurred on Tuesday, August 20th. The stock was sold at an average price of $55.57, for a total value of $110,806.58. Following the completion of the sale, the director now directly owns 43,010 shares in the company, valued at $2,390,065.70. The disclosure for this sale can be found here. In the last 90 days, insiders sold 14,192 shares of company stock worth $800,681. Corporate insiders own 3.67% of the company’s stock.

Anika Therapeutics Profile

Anika Therapeutics, Inc, together with its subsidiaries, provides orthopedic medicines for patients with degenerative orthopedic diseases and traumatic conditions in the United States and internationally. The company develops, manufactures, and commercializes therapeutic products based on its proprietary hyaluronic acid (HA) technology.

Recommended Story: Mutual Funds

Want to see what other hedge funds are holding ANIK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Anika Therapeutics Inc (NASDAQ:ANIK).

Institutional Ownership by Quarter for Anika Therapeutics (NASDAQ:ANIK)

Receive News & Ratings for Anika Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.